Satellite images are highlighting China’s death surge, showing an uptick in the number of vehicles parked at funeral homes. A Pfizer-made COVID-19 drug is soon to be removed from China’s health insurance list. Beijing is complaining the drug is “too expensive,” while the drugmaker’s CEO disagrees. Bipartisan efforts are working to counter the Chinese communist…
Is the White House’s Push for Paxlovid Evidence-Based?
The Biden administration and government agencies continue to push Pfizer’s COVID-19 emergency use authorization product, Paxlovid, even with insufficient new trial data showing effectiveness in the current population. Pfizer’s initial clinical trial for Paxlovid in 2021, which earned it an emergency use authorization (EAU) by the FDA, seemed quite promising. Results showed a relative risk reduction of progression…
US to Pay Pfizer $2 Billion for 3.7 Million More Courses of Paxlovid
The United States has struck a deal with Pfizer to pay the pharmaceutical giant almost $2 billion for 3.7 million more courses of Paxlovid. “The additional 3.7 million treatment courses are planned for delivery by early 2023,” the company announced. The Defense Department announced on Dec. 13 that Pfizer was awarded a $1,959,999,848 contract for Paxlovid. “Work…
Paxlovid, Advertised for Mass Use, Has Contraindications With Hundreds of Drugs
December 13, 2022
admin
AMERICACCP Virusjack askinsJohn Hughesmichael lamPaxlovidPUBLIC HEALTH INFORMATIONritonavirsabine hazanThe Food and Drug Administrationyusuf saleeby
0 Comment
One of the most robustly campaigned and well-known drugs for treating COVID is Paxlovid. Yet the drug’s limited clinical studies and numerous drug interactions raise questions of safety for COVID patients. Approved for Emergency Use Authorization (EUA) in December 2021 and promoted by the Food and Drug Administration (FDA), health officials, and politicians alike, Paxlovid…
Doctors Warn Pfizer COVID Treatment Paxlovid Can Interact With Common Medications
October 12, 2022
admin
AMERICABusiness & MarketsBusinesses in COVID-19CCP VirusCOVID-19PaxlovidPUBLIC HEALTH INFORMATIONUSUS News
0 Comment
The COVID-19 drug Paxlovid can have dangerous interactions with common medications used to treat cardiovascular disease, including certain statins, warned doctors in a new review paper. A paper published Wednesday in the Journal of the American College of Cardiology shows the combination of nirmatrelvir and ritonavir, or Pfizer’s Paxlovid, can interact with a number of…
FDA Asks Pfizer to Test Second Paxlovid Course in Patients With COVID-19 Rebound
The Food and Drug Administration (FDA) has asked Pfizer Inc. to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday. The drugmaker must produce the initial results of a randomized controlled trial of a second course of the…
Why Did Biden Get COVID Twice After 4 Shots, Paxlovid?
President Joe Biden was confirmed to be infected with COVID-19 on July 21, 2022. Biden had received four doses of vaccine, but why is he still infected with BA.5? Just a few days after his initial recovery, on July 30 Biden got COVID again: White House doctor Kevin O’Connor said that it was a Paxlovid…
Biden Tests Positive for COVID-19 Again, Returns to Isolation
President Joe Biden tested positive for COVID-19 again on Saturday morning, the president’s physician said. Dr. Kevin O’Connor, the White House physician, said in a letter that it’s a rare “rebound” case that usually is observed in a small percentage of patients treated with Paxlovid. Biden has experienced no reemergence of symptoms and “continues to…
Fauci Likely to Birth His Own COVID Variant After Paxlovid
July 13, 2022
admin
BrightCorona viruscoronavirus mutationcoronavirus mutationsCOVIDCOVID-19healthHealth ConditionsHealth ViewpointsInfectious DiseasesPaxlovid
0 Comment
Fauci experienced COVID-19 rebound after taking one course of Paxlovid. After his symptoms returned with a vengeance, he took a second course, which experts believe could be triggering SARS-CoV-2 mutations and resistance. STORY AT-A-GLANCE The U.S. Centers for Disease Control and Prevention issued a warning about the potential for COVID-19 rebound after Paxlovid treatment Dr….
Pfizer Stops Enrollment in Paxlovid Trial for Less Vulnerable COVID-19 Patients
Pfizer has announced it will stop enrollment in a clinical trial for Paxlovid—its COVID-19 antiviral pill—for standard-risk COVID-19 patients after the latest results suggested the drug did not reduce symptoms or hospitalizations and deaths to a statistically significant degree. Paxlovid, which consists of two different antiviral drugs—nirmatrelvir and ritonavir—is currently approved or authorized for conditional or…
-
Recent Posts
-
Archives
- May 2025
- April 2025
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- September 2013
- July 2013
- March 2013
- January 2013
- December 2012
- November 2012
- December 1
-
Meta